An Observational Study of Patients With Autoimmune Disease
NCT05842824 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500000
Last updated 2024-11-20
Summary
TARGET-AUTOIMMUNE is an observational research study to conduct a comprehensive review of outcomes for patients with autoimmune and related diseases. .
Conditions
Sponsors & Collaborators
-
Target PharmaSolutions, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-03-31
- Primary Completion
- 2038-12-31
- Completion
- 2038-12-31
More Related Trials
-
An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT04810754 ·Status: UNKNOWN ·Phase: PHASE2
-
Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment
NCT07102030 ·Status: RECRUITING
-
Comparative Autoantibody and Immunologic Cell Marker Study
NCT02422875 ·Status: ENROLLING_BY_INVITATION
-
Clinical Autoinflammatory Disease Cohort
NCT07126145 ·Status: NOT_YET_RECRUITING
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
NCT06828042 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of RD06-04 in Patients With Active Autoimmune Diseases
NCT06548620 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Atacicept Demonstrating Dose RESponSe
NCT01440231 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
NCT01305746 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
NCT01261793 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
NCT00624351 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249 ·Status: RECRUITING ·Phase: PHASE4
-
Acquired Immunodeficiency in ANCA Associated Vasculitis
NCT03514979 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
NCT00383214 ·Status: TERMINATED ·Phase: PHASE3
-
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05000216 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
NCT01262365 ·Status: COMPLETED ·Phase: PHASE3
-
Autoantibodies in Treatment with Immune Checkpoint Inhibitors (AUTENTIC)
NCT03868046 ·Status: COMPLETED
-
Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital
NCT04756492 ·Status: UNKNOWN
-
Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)
NCT03878303 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
NCT04433585 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Telitacicept in Early SLE
NCT05899907 ·Status: UNKNOWN ·Phase: PHASE4
-
ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
NCT02955615 ·Status: COMPLETED ·Phase: PHASE2
-
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06970951 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
NCT04726553 ·Status: UNKNOWN ·Phase: EARLY_PHASE1